HCW Biologics Inc. announced the successful development of second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly pancreatic and ovarian cancer, using its novel proprietary TRBC product discovery and development platform technology. These fusion molecules are designed to block checkpoint receptors while simultaneously engaging costimulatory receptors.
The company's pembrolizumab-based fusion molecule has been selected as a leading clinical product candidate. In preclinical studies, it exhibited potent anti-pancreatic cancer activities and outperformed pembrolizumab as monotherapy for cancer both in vitro and in humanized mouse models at well-tolerated dose levels.
Dr. Hing C. Wong, Founder and CEO, stated that this second-generation checkpoint inhibitor outperformed pembrolizumab in immune-cell activation and expansion, enhancement of immune cell infiltration into tumors, and immune cell cytotoxicity against cancer cells. Dr. Wong is scheduled to present these details at Nova Southeastern University on September 12, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.